India imports expand diagnostics demand

India’s diagnostics demand is becoming a supplier story as much as a healthcare story. India’s hospitals, reference labs and smaller testing networks are buying more of the tools that sit behind routine chemistry, immunoassay and molecular testing: reagents, cartridges, consumables, analyzers and automation. (ibef.org) Official and industry sources do not put that shift in the language of “picks and shovels,” but they do show a market growing fast enough to pull in more imported in-vitro diagnostics and lab equipment. (ficci.in) FICCI and BDO said in a November 2024 report that India’s diagnostics industry is likely to reach $25 billion by 2028 from $13 billion. The Indian Brand Equity Foundation, a government-backed industry body, said the broader diagnostic equipment market is projected to reach about $6 billion by 2027, up from $4 billion in calendar 2023. (cdsco.gov.in) ### Where is the demand showing up? India’s demand is showing up across both routine and higher-complexity testing categories. Siemens Healthineers’ India diagnostics business lists chemistry, immunoassay, hematology, molecular, urinalysis and blood-gas systems for laboratories “of any size,” a sign of the breadth of addressable demand rather than a single niche segment. (ibef.org) IBEF said rising numbers of medical facilities are boosting demand for medical devices, while diagnostics remains one of the more visible healthcare buildout categories. That matters for suppliers because analyzers do not move alone: they pull recurring sales of assay kits, calibrators, controls, sample-prep products and service support. (ficci.in) ### Why does this matter more for consumables suppliers than for one-time equipment sellers? Reagents and consumables are the repeat-purchase layer of the market. A lab may buy an analyzer once every several years, but it keeps buying test-specific inputs as long as the installed instrument base is running. FICCI-BDO’s estimate of a jump to $25 billion by 2028 suggests the opportunity is not limited to headline equipment makers. (siemens-healthineers.com) It extends to suppliers of sample tubes, controls, plastics, kits and other recurring inputs that labs need to maintain throughput. That is the part of the market social posts are capturing when they point to “picks and shovels” demand. ### If India is importing more, what does the regulatory burden look like? (ibef.org) India regulates in-vitro diagnostics through the Central Drugs Standard Control Organisation. CDSCO says import, manufacturing, sale and distribution of in-vitro diagnostic medical devices are governed under the Drugs and Cosmetics Act and the Medical Devices Rules, 2017, with import licences filed through the online portal in Form MD-14 for grant of licence in MD-15. A 2026 CDSCO draft guidance for IVD imports gives a clearer picture of what importers have to manage. The document sets out application pathways, classification, required documents, timelines and a list of common non-compliance issues, including supporting certificates, instructions for use and other dossier materials. (ficci.in) For overseas suppliers, that means market access depends not only on product demand but also on local regulatory execution and document quality. ### What makes India attractive but not frictionless? India is attractive because the healthcare and medtech base is getting bigger. (cdsco.gov.in) IBEF said India’s medical devices market was estimated at $11 billion in 2022 and is expected to reach $50 billion by 2030, with policy support including the National Medical Device Policy 2023 and 100% foreign direct investment allowed in medical devices. The friction is operational. CDSCO’s import framework means suppliers need local registration discipline, distributor capability and complete technical documentation. In practice, companies selling imported diagnostics into India need more than demand forecasts; they need a local route to market that can handle licensing, port clearance, post-sale support and quality paperwork. (cdsco.gov.in) That is especially true for higher-end analyzers and molecular systems that depend on continuing reagent supply. ### What should suppliers watch next? CDSCO’s 2026 draft import guidance says stakeholder comments are due within 15 days of publication, making the import process itself a live issue for companies selling IVD products into India. (ibef.org) The next practical checkpoint for suppliers is whether the final guidance changes document, checklist or compliance expectations for import licence applications filed through CDSCO’s online systems. (cdsco.gov.in 1) (cdsco.gov.in 2)